Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name	of entity Adherium Limited
ABN	24 605 352 510

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	George Baran
Date of last notice	4 April 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect		
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Trudell Medical Limited - Mr Baran has a 33.33% beneficial interest in Trudell Medical Limited		
Date of change	27 May 2024		
No. of securities held prior to	- 73,538,685 Fully paid ordinary shares		
change	- 699,064 Options over fully paid ordinary shares, exercisable at \$0.3285 each and expiring on 29 January 2027 Expiry of unlisted options on 31 March 2024		
Class	- Fully Paid Ordinary Shares		
	- Unlisted Options exercisable at 3 cents, expiring on 30 June 2025		
Number acquired	- 50,000,000 Fully Paid Ordinary Shares		
	- 50,000,000 Unlisted Options exercisable at 3 cents, expiring on 30 June 2025		

⁺ See chapter 19 for defined terms.

Number disposed Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil - \$0.02 per Fully Paid Ordinary Shares - Nil consideration for Options – free attaching options for every new share subscribed under the Rights Offer.
No. of securities held after change	 123,538,685 Fully paid ordinary shares 699,064 Options over fully paid ordinary shares, exercisable at \$0.3285 each and expiring on 29 January 2027 Expiry of unlisted options on 31 March 2024 50,000,000 Unlisted Options exercisable at 3 cents, expiring on 30 June 2025
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Subscription to non-renounceable rights entitlement in April 2024, with free attaching options for every new share subscribed under the Rights Offer.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 - $^+$ Closed period

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.

Were the interests in the securities or contracts detailed above	No.
traded during a +closed period where prior written clearance	
was required?	
If so, was prior written clearance provided to allow the trade	N/A
to proceed during this period?	
If prior written clearance was provided, on what date was this	N/A
provided?	
1	1

⁺ See chapter 19 for defined terms.